Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Showing results (101-110 of 299) with videos related to

Pageof 30
Sort By:
Blood Reviews|August 31, 2015
Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?Javeed Iqbal, Ryan Wilcox, Hina Naushad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer InstitutesJulie M Vose, Laura A Levit, Patricia Hurley, et al.
Leukemia & Lymphoma|October 11, 2014
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphomaKyriakos P Papadopoulos, Coumaran Egile, Rodrigo Ruiz-Soto, et al.
Cancer|July 29, 2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaRichard R Furman, Peter Martin, Jia Ruan, et al.
British Journal of Haematology|October 1, 2010
Late relapse in patients with diffuse large B-cell lymphomaJulie M Vose, Dennis D Weisenburger, Fausto R Loberiza, et al.
British Journal of Haematology|April 25, 2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II studyJulie M Vose, Siddhartha Ganguly, Philip J Bierman, et al.
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decadesVijaya Raj Bhatt, Fausto R Loberiza, Hongmei Jing, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2010
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial responseMarcie R Tomblyn, Marian Ewell, Christopher Bredeson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 4, 2012
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphomaJulie M Vose, Philip J Bierman, Fausto R Loberiza, et al.
Pageof 30

Showing results (101-110 of 299) with videos related to

Sort By:
Pageof 30
Blood Reviews|August 31, 2015
Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?Javeed Iqbal, Ryan Wilcox, Hina Naushad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer InstitutesJulie M Vose, Laura A Levit, Patricia Hurley, et al.
Leukemia & Lymphoma|October 11, 2014
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphomaKyriakos P Papadopoulos, Coumaran Egile, Rodrigo Ruiz-Soto, et al.
Cancer|July 29, 2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaRichard R Furman, Peter Martin, Jia Ruan, et al.
British Journal of Haematology|October 1, 2010
Late relapse in patients with diffuse large B-cell lymphomaJulie M Vose, Dennis D Weisenburger, Fausto R Loberiza, et al.
British Journal of Haematology|April 25, 2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II studyJulie M Vose, Siddhartha Ganguly, Philip J Bierman, et al.
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decadesVijaya Raj Bhatt, Fausto R Loberiza, Hongmei Jing, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2010
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial responseMarcie R Tomblyn, Marian Ewell, Christopher Bredeson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 4, 2012
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphomaJulie M Vose, Philip J Bierman, Fausto R Loberiza, et al.
Pageof 30